MedTrace Logo

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

NCT06408285 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-10-29

No results posted yet for this study

Summary

This is a dose escalation trial. The dosing regimen involves a single-dose study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3927 powder for inhalation in healthy adults subjects.

Conditions

Interventions

DRUG

TQC3927 powder for inhalation

TQC3927 is a targeted inhibitor.

DRUG

TQC3927 powder for inhalation placebo

TQC3927 powder for inhalation placebo contains no active substance.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-22
Primary Completion
2024-08-19
Completion
2024-08-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408285 on ClinicalTrials.gov